Objective: Heart failure with preserved ejection fraction (HFpEF) is a growing concern among the elderly population, significantly impacting morbidity and mortality rates. This study aimed to screen and investigate the characteristics and prognosis of early-stage HFpEF in the elderly.
Methods: A total of 1789 community-dwelling individuals aged over 65 from northern Shanghai were enrolled. According to American Heart Association (AHA) guidelines, participants were classified into four groups: HFpEF stage 0, HFpEF stage A, HFpEF stage B and HFpEF stage C. Major endpoints included major adverse cardiovascular events (MACEs), all-cause death and cardiovascular death.
Results: After a mean follow-up period of 7.10 ± 1.27 years, 1623 elderly subjects were included [HFpEF stage 0 (10.3%), HFpEF stage A (16.3%), HFpEF stage B (60.6%) and HFpEF stage C (12.8%)]. Patients with HFpEF stage A, HFpEF stage B and HFpEF stage C exhibited more MACEs than those in HFpEF stage 0 (P < 0.01). Patients with HFpEF stage C had a significantly higher cardiovascular (P < 0.001) and all-cause death ratio (P < 0.01). With HFpEF stage 0 as a reference, the increases in MACEs were significantly associated with HFpEF stage A [hazard ratio (HR): 2.97, 95% confidence interval (CI) (1.13, 7.82), P < 0.05], HFpEF stage B [HR: 2.69, 95% CI (1.09, 6.64), P < 0.05] and HFpEF stage C [HR: 4.86, 95% CI (1.88, 12.59), P < 0.01] in the Cox regression analysis. Our finding remains unaltered in the sensitivity analysis, with no interaction for effectiveness.
Conclusions: Compared with those with HFpEF stage 0, patients with HFpEF, whether in stage B or C, exhibit significantly higher cardiovascular and all-cause mortality in the elderly. This study underscores the importance of early-stage HFpEF screening, particularly in older, asymptomatic stage B individuals.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ehf2.15060 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Progress of echocardiography in the evaluation of left atrial function in patients with heart failure with preserved ejection fraction: a narrative review.
Quant Imaging Med Surg
December 2024
Department of Cardiovascular Ultrasound, Fourth Affiliated Hospital, Harbin Medical University, Harbin, China.
Background And Objective: About half of all heart failures are heart failures with preserved ejection fraction (HFpEFs). As the population ages and metabolic disorders become more common, the prevalence of HFpEF continues to increase annually. Patients with HFpEF typically show a decline in various reserve capacities after exercise.
View Article and Find Full Text PDFArticle Synopsis
- * Affected individuals typically experience more severe heart failure symptoms and poorer outcomes, influencing treatment choices based on how severe the dysfunction is.
- * Echocardiography is a key tool for evaluating left atrial function, and analyzing strain parameters can help identify early issues and guide prognosis and treatment strategies in HFpEF.
Inter-atrial block as a predictor of adverse outcomes in patients with HFpEF.
ESC Heart Fail
December 2024
Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre+ (MUMC+), Maastricht, The Netherlands.
Article Synopsis
- The study investigates the prevalence and impact of inter-atrial block (IAB) as an indicator of electrical dysfunction in patients with heart failure with preserved ejection fraction (HFpEF).
- It examines two groups: ambulatory HFpEF patients and those recently hospitalized, assessing their risk for adverse events like hospitalization and death.
- Findings suggest that different stages of electrical atrial dysfunction significantly predict adverse outcomes, indicating that patients without dysfunction might require less intensive management.
Drug-Induced Delirium Associated With Sacubitril/Valsartan in a Patient With Chronic Kidney Disease: A Case Report.
Cureus
October 2024
Internal Medicine, St Vincent Medical Center, Bridgeport, USA.
Article Synopsis
- Drug-induced neuropsychiatric symptoms, like delirium and hallucinations, are common, especially in patients with multiple health issues and taking many medications.
- Sacubitril/valsartan is a heart failure drug that helps reduce hospitalizations, particularly in patients with preserved ejection fraction (HFpEF).
- A case report details a 79-year-old male with HFpEF and end-stage kidney disease who experienced visual hallucinations after beginning treatment with sacubitril/valsartan.
Moderately Increased Left Ventricular Filling Pressure Suggesting Early Stage of Heart Failure with Preserved Ejection Fraction in Patients with Invasively Assessed Coronary Microvascular Dysfunction.
J Clin Med
November 2024
Pre-Clinical Research Center, Wrocław Medical University, Karola Marcinkowskiego 1, 53-368 Wroclaw, Poland.
: With modern diagnostic tools, incidence ischemia with no obstructive coronary atherosclerosis (INOCA) and heart failure with preserved ejection fraction (HFpEF) are found to be much higher than previously believed, and-as they lead to adverse cardiovascular outcomes-their causes and development are subjects of ongoing research. There is growing evidence that coronary microvascular dysfunction might be the underlying cause of both INOCA and HFpEF. : In 65 patients with effort angina but no obstructive coronary artery disease, the index of microvascular resistance and coronary flow reserve were measured invasively in the LAD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!